Abbreviations: MCS = mental component summary; PCS = physical component summary; s.d. = standard deviation.
Allogeneic hematopoietic stem cell transplantation (HSCT) is still the only treatment that allows complete recovery from thalassemia. Increased knowledge of the immunogenetic mechanisms involved and better conditioning regimens have considerably reduced the incidence of transplant-related mortality and GvHD. [1] [2] [3] Despite better outcomes, the transplant procedure with its complications significantly contribute to impairment of health-related quality of life (HRQoL), a multidimensional construct referring to patients' perceptions of the impact of disease and treatment on their physical, psychological and social well being. 4 HRQoL and return to normal life following HSCT for thalassemia has rarely been investigated. [5] [6] [7] [8] [9] [10] [11] Moreover, there are no reports of differences in HRQoL and socio-demographic profiles between transplanted thalassemia patients and their sibling donors. We investigated global physical health and socio-demographic characteristics in 71 transplanted thalassemia patients, their sibling donors and a group of 71 age and sex matched conventionally treated thalassemia patients. The two groups of thalassemia patients were recruited from larger studies of HRQoL that have been published elsewhere. 10 Global health status was assessed by physical component summary and mental component summary (MCS) scores, which represent the aggregation of eight domains on the 36-item Short-Form Health Survey (SF-36) of the medical outcomes study. Scores were computed according to the instructions in the User Manual. 12 The results obtained in the three groups were compared using Wilcoxon/Kruskal-Wallis tests. Participants were also asked to fill in a survey requesting information about employment status, working load, achievement of upper education level (high school, university degree or higher), number of pregnancies, marital and living status and participation in social networks. Comparisons were analyzed using a contingency table. Surveys were administered at a median time of 21 years (range 12-29) after HSCT or bone marrow donation.
Characteristics of the three groups are summarized in Table 1 . Mean age was similar in transplanted patients (33) and their sibling donors (35). Median follow-up after HSCT was 21.8 years 0.7-26.5 years). The incidence of acute GvHD (grades II-IV) was 34%; chronic GvHD affected 18% of the patients, but in most of them (60%) was staged as limited disease. The GvHD prophylactic regimen consisted of cyclosporine A, steroids and/or short-course methotrexate. None of long-term survivors were any longer on immunosuppression. The rate of pregnancies was lower among transplanted patients (15%) compared with their donors (31%) and thalassemia patients (24%). This finding was expected and a direct consequence of chemotherapy induction regimens administered before transplantation.
No significant differences were observed between patients and their donors for achievement of upper educational levels and percentage of individuals married or living with a partner. A significantly higher percentage was observed for employment in the group of transplanted patients (70.4%) compared with their donors (59.1%) and the conventionally treated patients (40.8%) (P = 0.001). The percentage of individuals holding a full-time working position was 62% in the group of transplanted patients, 49.3% in the group of donors and only 25.3% in the thalassemia patients (P = 0.001). Some transplanted patients with active comorbidities are included on special priority employment lists and the employers who hire them benefit from tax cuts. However, the high employment rate in most patients may also be a consequence of the strong motivational drive of patients with a history of chronic disease, who consider HSCT as an opportunity for a new beginning. Interestingly, transplanted patients took a more active part in social forums (Facebook and Twitter) than their donors (73.2 vs 49.3%, P = 0.001). A similar percentage was observed in the group of conventionally treated patients (77.5%). Since social networking websites give people the opportunity to express their views, making them feel independent and self-confident, activity on social media confirms a return to a normal life in terms of relationship building. Physical health scores of transplanted patients were not statistically different from those of their sibling donors (68.4 ± 8.4 vs 70.4 ± 6; P = NS) but were significantly higher in comparison with conventionally treated thalassemia patients (68.4 ± 8.4 vs 61.6 ± 8.2; P = 0.01). No significant differences were observed between the three groups for MCS scores. Overall, patients transplanted for thalassemia seem to achieve a return to normal HRQoL with physical and mental profiles comparable to their sibling donors. Educational level, working position and social life were also similar, if not better than that reported by their donors. These findings suggest that thalassemia patients return to normal life after related HSCT. Nevertheless, because of the increasing life expectancy of these patients and the future prospect of gene-therapy, the decision of whether or not to transplant a patient remains a clinical dilemma.
